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A combination of ampicillin and aminoglycoside for early-onset
neonatal sepsisStreptococcus agalactiae, which is known as group B
streptococcus (GBS), has traditionally been the leading cause
of neonatal morbidity and mortality [1]. The gastrointestinal
tract, especially the rectum, is considered as the major reser-
voir for the colonized vagina [2]. The Centers for Disease
Control and Prevention issued recommendations for intra-
partum prophylaxis to prevent perinatal GBS in 2010 [3]. This
was also recommended by the American College of Obste-
tricians and Gynecologists, the American Academy of Pedia-
trics, the American College of Nurse-Midwives, the American
Academy of Family Physicians, and the American Society for
Microbiology [4]. With improved obstetrical management and
evidence-based use of intrapartum antibiotics, early-onset
neonatal sepsis caused by GBS is becoming less frequent
[5]. However, early-onset sepsis remains one of the most
common causes of neonatal morbidity and mortality in the
preterm population.
Any strategy to identify the risk, confirm the diagnosis, and
prevent the occurrence is welcome, although there are chal-
lenges for clinicians, including: (1) promptly identifying
neonates with a high likelihood of sepsis and initiating anti-
microbial therapy; (2) distinguishing “high risk” healthy-
appearing infants or infants with clinical signs that do not
require treatment; and (3) discontinuing antimicrobial therapy
once sepsis is deemed unlikely [5]. In our previous reports, we
developed a useful tool (chip-based multiplexed immunoassay
using liposomal nanovesicles) which might provide an
opportunity for early detection of the pathogens causing
neonatal sepsis through an antepartum or intrapartum evalua-
tion [6e8], because the identification of neonates at risk for
early-onset sepsis is frequently based on a constellation of
perinatal risk factors that are neither sensitive nor specific, and
diagnostic tests for neonatal sepsis have a poor positive pre-
dictive accuracy [5]. Because of these challenges, clinicians
often treat well-appearing infants for extended periods with an
optimal treatment, such as broad-spectrum antimicrobial
agents (ampicillin and an aminoglycoside), even when bacte-
rial cultures are negative [5].
Research by Tsai et al, published in the Taiwan Journal of
Obstetrics and Gynecology in 2012, showed that the incidence
of non-GBS and antibiotic-resistant early-onset sepsis in1028-4559/$ - see front matter Copyright  2013, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2013.01.001preterm, low-birth-weight, or very low-birth-weight neonates
was significantly increased [9]. The paper provided useful
information that would encourage obstetricians and neo-
natologists to reconsider the severity of non-GBS neonatal
sepsis.
First, Escherichia coli might be one of the most common
pathogens in non-GBS neonatal infections, especially in pre-
term infants. Second, the overall incidence of E. coli neonatal
sepsis remained stable after the introduction of intrapartum
antibiotics prophylaxis, but increased in very low-birth-weight
infants. Early-onset E. coli neonatal sepsis is more common in
premature and very low-birth-weight infants and is more likely
to be associated with intrapartum fever, preterm premature
rupture of membranes, and sepsis onset on the first day of life
than non-E. coli neonatal sepsis. Third, nearly 80% of E. coli
neonatal sepsis was ampicillin-resistant and 16% was
gentamicin-resistant, and all of these patients had a history of
antepartum and intrapartum antibiotic exposure [9].
Based on the above finding, the guideline published in the
journal Pediatrics in May 2012 can be argued against, because
this guideline suggested that the optimal treatment of infants
with suspected early-onset sepsis is broad-spectrum anti-
microbial agents (ampicillin and an aminoglycoside) [5]. A
combination of ampicillin and an aminoglycoside (usually
gentamicin) is generally used as initial therapy, and it also has
synergistic activity against GBS and Listeria monocytogenes
[5]. If the report by Dr Tsai and colleagues [9] is reproducible
in other hospitals in Taiwan, then other antibiotics should be
used in place of the suggested optimal treatment. For example,
third-generation cephalosporins (e.g., cefotaxime) represent a
reasonable alternative to an aminoglycoside. However, this
alternative treatment might not have any advantage, because
several studies have reported rapid development of resistance
when cefotaxime was used routinely for the treatment of early-
onset neonatal sepsis [10], and extensive/prolonged use of
third-generation cephalosporins is a risk factor for invasive
candidiasis [5].
Neonatal sepsis is still the biggest challenge, not only for
obstetricians, but also for neonatologists. One report might not
change our treatment policy [9], but it is worthy of our
attention.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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